Abstract Library

#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus

Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Spada F, Pisa E, Lorizzo K, Barberis M, Fazio N,

Keywords: mTOR,

#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).

Conference:

Presenting Author:

Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,

Keywords: neuroendocrine, ERCC1, Ki 67 ,